Association of Interferon-Gamma Inducible Protein 10 Polymorphism with Treatment Response to Pegylated Interferon in HBeAg-Positive Chronic Hepatitis B. Issue 2 (February 2016)

• Record Type: Journal Article
• Authors: Limothai, Umaporn; Chuaypen, Natthaya; Khlaiphuengsin, Apichaya; Posuwan, Nawarat; Wasitthankasem, Rujipat; Poovorawan, Yong; Tangkijvanich, Pisit
• Is Part Of: Antiviral therapy. Volume 21:Issue 2(2016)
• Page Start: 97
• Page End: 106
• Publication Date: 2016-02
• Subjects: Antiviral agents -- Periodicals; Antiviral Agents -- therapeutic use; Virus Diseases -- therapy; Viruses -- drug effects; Antiviral agents; Periodical; Electronic journals; Periodicals; 616.9106
• DOI: 10.3851/IMP2992
• Languages: English
• ISSNs: 1359-6535

Abstract

Background: Interferon-gamma inducible protein 10 (IP-10) plays an important role in the clinical outcome of chronic hepatitis B (CHB). This study aimed to investigate the association between single nucleotide polymorphisms (SNPs) G-201A of the IP-10 gene and treatment response to pegylated interferon (PEG-IFN) in patients with hepatitis B e antigen (HBeAg)-positive CHB. Methods: We retrospectively analysed data of patients with HBeAg-positive CHB treated with PEG-IFN for 48 weeks. Virological response (VR) was defined as HBeAg clearance and HBV DNA <2, 000 IU/ml at 24 weeks post-treatment. The SNPs G-201A, IFNL3 (rs12979860) and HLA-DPA1 (rs3077) were assessed. Results: Among 107 patients, VR was achieved in 45 (42.1%) patients. Hepatitis B surface antigen (HBsAg) clearance and decline (<100 IU/ml) were observed in 10 (9.3%) and 22 (20.6%) patients, respectively. The distribution of GG, GA and AA genotypes of G-201A was 76.6%, 19.6% and 3.7%, respectively. Patients with GG genotype, compared to those with non-GG genotype, achieved higher VR rate (48.8% versus 19.2%; P =0.011), decreased HBsAg (25.6% versus 4.0%; P =0.019), and demonstrated a trend in HBsAg clearance (11.0% versus 4%; P =0.294). Patients with GG genotype had more rapid HBsAg decline and higher baseline serum IP-10 levels than those with non-GG genotype (432.2 ±339.0 versus 257.3 ±145.7 pg/ml; P =0.028). SNPs rs12979860 and rs3077 were not associated with VR. Logistic regression analysis suggested that SNP G-201A was an independent predictor of VR (odds ratio 3.81, 95% CI 1.31, 11.12; P =0.014). Conclusions: Data from this study demonstrated for the first time that IP-10 polymorphism is independently associated with treatment response to PEG-IFN in patients with HBeAg-positive CHB.